Delcath Systems (NASDAQ:DCTH) Upgraded to "Hold" at StockNews.com

StockNews.com upgraded shares of Delcath Systems (NASDAQ:DCTH - Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday morning.

A number of other brokerages also recently issued reports on DCTH. Craig Hallum began coverage on shares of Delcath Systems in a research report on Friday, June 28th. They issued a buy rating and a $18.00 price objective on the stock. Stephens reaffirmed an overweight rating and issued a $25.00 price objective on shares of Delcath Systems in a research report on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a buy rating and issued a $22.00 price objective on shares of Delcath Systems in a research report on Tuesday, August 6th.

Delcath Systems Price Performance

NASDAQ DCTH traded up $0.27 during trading on Friday, reaching $9.14. 202,903 shares of the company's stock traded hands, compared to its average volume of 255,090. The firm has a market cap of $253.86 million, a price-to-earnings ratio of -3.40 and a beta of 0.78. The company's 50 day simple moving average is $8.90 and its two-hundred day simple moving average is $7.20. Delcath Systems has a 12-month low of $2.25 and a 12-month high of $11.74.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its earnings results on Monday, August 5th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.12). Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. The business had revenue of $7.77 million for the quarter, compared to analysts' expectations of $5.00 million. During the same period last year, the business posted ($0.58) EPS. Research analysts expect that Delcath Systems will post -1.67 earnings per share for the current fiscal year.

Institutional Trading of Delcath Systems

Several large investors have recently bought and sold shares of DCTH. Rosalind Advisors Inc. lifted its stake in Delcath Systems by 155.1% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company's stock valued at $22,184,000 after acquiring an additional 1,611,561 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Delcath Systems during the 4th quarter valued at approximately $962,000. BVF Inc. IL lifted its stake in Delcath Systems by 23.1% during the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company's stock valued at $5,734,000 after acquiring an additional 225,918 shares during the period. Shellback Capital LP acquired a new stake in Delcath Systems during the 2nd quarter valued at approximately $1,353,000. Finally, Vanguard Group Inc. lifted its stake in Delcath Systems by 31.0% during the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company's stock valued at $3,261,000 after acquiring an additional 161,678 shares during the period. Hedge funds and other institutional investors own 61.12% of the company's stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.